OTC Markets OTCPK - Delayed Quote USD

Biora Therapeutics, Inc. (BIOR)

0.2200
0.0000
(0.00%)
At close: June 5 at 8:00:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Aditya P. Mohanty M.B.A. CEO & Director 984.14k -- 1967
Mr. Eric d'Esparbes Chief Financial Officer 748.26k -- 1968
Mr. Clarke Neumann J.D. Senior VP, General Counsel & Secretary 724.62k -- 1964
Mr. Kevin Howe Ph.D. Senior VP of Strategic Operations -- -- --
Dr. Paul Shabram M.B.A. Head of Technical Operations -- -- --
Mr. James Knight M.B.A. Head of Business Development -- -- --

Biora Therapeutics, Inc.

4330 La Jolla Village Drive
Suite 300
San Diego, CA 92122
United States
833 727 2841 https://www.bioratherapeutics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
58

Description

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. On December 27, 2024, Biora Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Corporate Governance

Biora Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

June 19, 2025 at 10:59 AM UTC - June 25, 2025 at 12:00 PM UTC

Biora Therapeutics, Inc. Earnings Date

Recent Events

December 30, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 10, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 15, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 14, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

October 23, 2024 at 12:00 AM UTC

DEF 14A: Proxy Statements

October 11, 2024 at 12:00 AM UTC

PRE 14A: Proxy Statements

October 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 16, 2024 at 12:00 AM UTC

DEF 14A: Proxy Statements

September 13, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 5, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers